Grufity logo
Grufity logo
LPCN

LPCN - Lipocine Inc Stock Price, Fair Value and News

$2.31+0.02 (+0.87%)
Market Closed as of 16 Jun 2026, 04:00 pm ET

41/100

LPCN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

41/100

LPCN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

LPCN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

LPCN Price Action

Last 7 days

12.8%

Last 30 days

1.8%

Last 90 days

-70.0%

Trailing 12 Months

-26.3%

LPCN RSI Chart

LPCN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

LPCN Valuation

Market Cap

17.1M

Price/Earnings (Trailing)

-1.5

Price/Sales (Trailing)

8.66

EV/EBITDA

-1.06

Price/Free Cashflow

-1.7

LPCN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

LPCN Fundamentals

LPCN Revenue

Rev. Growth (Yr)

-73.17%

Rev. Growth (Qtr)

-67.83%

LPCN Earnings

Earnings (TTM)

-11.4M

Earnings Growth (Yr)

-96.9%

Earnings Growth (Qtr)

-54.93%

LPCN Profitability

EBT Margin

-578.47%

Return on Equity

-50.08%

Return on Assets

-45.09%

Free Cashflow Yield

-58.7%

LPCN Investor Care

Shares Dilution (1Y)

39.71%

Diluted EPS (TTM)

-1.88

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2026----
20258.1M5.1M-2.0M
20245.8M8.5M-11.2M
20233.2M---
202212.2M8.3M4.4M500.0K
2021---16.1M
2019--5.7M10.9M
20184.1M428.0K428.0K428.0K
2012-4.6M6.2M7.7M
2011---3.1M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Lipocine Inc

LPCN
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1154 for postpartum depression; LPCN 2101 for women with epilepsy; and LPCN 1148, a novel prodrug of testosterone, testosterone laurate for the management of decompensated cirrhosis. It also develops LPCN 1144, an oral prodrug of androgen receptor modulator for the treatment of non-cirrhotic non-alcoholic steatohepatitis, which has completed Phase II testing; LPCN 1111, an oral TRT product of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical testing; and LPCN 1107, an oral hydroxy progesterone caproate product for the prevention of recurrent preterm birth. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.
 CEO
 WEBSITElipocine.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES15

Lipocine Inc Frequently Asked Questions

LPCN is the stock ticker symbol of Lipocine Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jun 15 2026, market cap of Lipocine Inc is 17.12 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Jun 15 2026, LPCN's PE ratio (Price to Earnings) is -1.5 and Price to Sales (PS) ratio is 8.66. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LPCN PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Lipocine Inc has provided -0.326 (multiply by 100 for percentage) rate of return.